Genetic testing could streamline heart therapy:
This article was originally published in Clinica
Executive Summary
A genetic test for the ACE (angiotensin converting enzyme) gene could predict which patients are likely to benefit from beta blockers in the treatment of congestive heart failure, according to a US study. Researchers from the University of Pittsburgh in Pennsylvania evaluated 328 patients with heart failure who were being treated with either ACE inhibitors, angiotensin receptor blockers or beta blockers. They found that patients with two deletion (D) alleles, known as ACE DD, had "dramatic benefits" when using beta blockers compared with the other medication. The study appeared in Circulation (March 27).
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.